Permanente physician leader Stephen Parodi, MD, was among the experts discussing how technology helps drive preventive care and healing as care extends into the home.
On the front lines of Kaiser Permanente’s pandemic response, infectious disease leaders play a key role in sharing research, building guidelines, and charting a national roadmap to flatten the coronavirus curve.
This year’s flu season arrives with the backdrop of a pandemic, prompting physicians and health officials to get creative in promoting flu shots and finding safe ways to deliver the vaccine, according to a recently published Washington Post story.
Stephen Parodi, MD, shared his insights on the field of epidemiology and what makes it personally fulfilling for him in U.S. News & World Report.
Citing record numbers of COVID-19 cases in California’s hospital system – including 800 patients hospitalized at Kaiser Permanente medical centers in California – Stephen Parodi, MD, told CNN International that it’s time to reinstate some of the coronavirus safety measures that had been lifted in recent weeks.
Stephen Parodi, MD, executive vice president of The Permanente Federation and national infectious disease leader at Kaiser Permanente, recently discussed the effects of disparate approaches to COVID-19 interventions across the United States with The Wall Street Journal.
Stephen Parodi, MD, national infectious disease leader for Kaiser Permanente, commented in Fierce Healthcare on Kaiser Permanente’s multipronged COVID-19 suppression strategy, which was outlined in a NEJM Catalyst article earlier this week. That strategy includes 8 key capabilities health systems need to consider as the country reopens.
In an article published this week in NEJM Catalyst, Kaiser Permanente physicians and leaders acknowledge the conundrum of reopening the country for business while preventing successive waves of coronavirus infection, and describe the next strategic phase in the battle against the COVID-19 pandemic: disease suppression.
Stephen Parodi, MD, an associate executive director of The Permanente Medical Group in Northern California, told Voice of America that Kaiser Permanente is working with “light speed” to build a new 7,000-square-foot testing lab in Berkeley.
Stephen Parodi, MD, associate executive director of The Permanente Medical Group and national infectious disease leader for Kaiser Permanente, spoke with CBSN recently about why trials with remdesivir and other drugs matter. CBSN is the CBS News 24/7 digital streaming service.